Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

View Full Paper
Ask AI
Bookmark
Share

Authors

PHPaul J. HampelAKAmber B. KoehlerTHTalal Hilal

Discussion

Loading...

Member takes

Overview

Analysis reveals Venetoclax-obinutuzumab treatment shows similar OS in chronic lymphocytic leukemia patients compared to age-matched general population.

Key Points

  • Patients receiving venetoclax-obinutuzumab showed high event-free survival rates beyond 5 years.
  • The study included 154 patients with varying TP53 disruption rates affecting outcomes.
  • Overall survival was comparable to that of the general population, indicating effective treatment.
  • Prolonged analyses highlighted concerns around TP53 disruptions and their impact on survival rates.

Cite This Study

Hampel et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1b2https://doi.org/10.1182/blood-2025-3905
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025
  2. 2Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group2025 · 4 citations
  3. 3Long-term immune reconstitution and final 1-year follow-up after fixed-duration venetoclax-obinutuzumab (VenO) in first-line (1L) chronic lymphocytic leukemia (CLL): Results from the Phase III CRISTALLO trial2025
  4. 4Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers of slovakia2025
  5. 5Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia2025